139 related articles for article (PubMed ID: 30143953)
1. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.
Mennini FS; Bini C; Marcellusi A; Del Vecchio M
Clin Drug Investig; 2018 Oct; 38(10):967-976. PubMed ID: 30143953
[TBL] [Abstract][Full Text] [Related]
2. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
4. Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
Bastiaannet E; Battisti N; Loh KP; de Glas N; Soto-Perez-de-Celis E; Baldini C; Kapiteijn E; Lichtman S
J Geriatr Oncol; 2019 May; 10(3):389-397. PubMed ID: 30025821
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
Cao Y; Afzal MZ; Shirai K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
8. Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
Gibson E; Koblbauer I; Begum N; Dranitsaris G; Liew D; McEwan P; Tahami Monfared AA; Yuan Y; Juarez-Garcia A; Tyas D; Lees M
Pharmacoeconomics; 2017 Dec; 35(12):1257-1270. PubMed ID: 28866758
[TBL] [Abstract][Full Text] [Related]
9. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y; Hamamoto S; Sugiyama Y; Tomiyama N; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Kubota H; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Yasui T; Kimura K
Int J Urol; 2023 Oct; 30(10):866-874. PubMed ID: 37278575
[TBL] [Abstract][Full Text] [Related]
10. Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy.
Kersh AE; Schuchter LM; Elenitsas R; Chu EY
Immunotherapy; 2020 Sep; 12(13):951-956. PubMed ID: 32772616
[No Abstract] [Full Text] [Related]
11. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
[TBL] [Abstract][Full Text] [Related]
13. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
14. [Checkpoint inhibitors-indications and application in melanoma patients].
Lamos C; Hunger RE
Z Rheumatol; 2020 Oct; 79(8):818-825. PubMed ID: 32926216
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
[TBL] [Abstract][Full Text] [Related]
16. Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease.
Weiss J; Kirchberger MC; Heinzerling L
Cancer Med; 2020 Sep; 9(17):6132-6140. PubMed ID: 32649807
[TBL] [Abstract][Full Text] [Related]
17. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab.
Choi JS; Chen M; McQuade JL; Appelbaum E; Gidley PW; Nader ME
Head Neck; 2020 Nov; 42(11):E35-E42. PubMed ID: 32888241
[TBL] [Abstract][Full Text] [Related]
18. Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report.
Núñez Abad M; Saval Victoria A; Franco La Rosa M; Berrocal A
Melanoma Res; 2021 Feb; 31(1):88-91. PubMed ID: 33234847
[TBL] [Abstract][Full Text] [Related]
19. LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials.
Zhao BW; Zhang FY; Wang Y; Chen GM; Nie M; Zhao ZK; Chen XJ; Jiang KM; Nie RC; Chen YB
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291763
[No Abstract] [Full Text] [Related]
20. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.
Stein C; Burtey S; Mancini J; Pelletier M; Sallée M; Brunet P; Berbis P; Grob JJ; Honoré S; Gaudy C; Jourde-Chiche N
Nephrol Dial Transplant; 2021 Aug; 36(9):1664-1674. PubMed ID: 32941608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
